Skip to main content
Publications
Mareque M, Montesinos P, Font P, Guinea JM, De La Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Cain L, Romanus D, Suryanarayan K, Rajkumar V, Odom D, Gnanasakthy A, Dimopoulos MA. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial. Eur J Haematol. 2020 May;104(5):443-58. doi: 10.1111/ejh.13379.
Jimenez-Murcia S, Granero R, Larrea ST, Sauvaget A, Grall-Bronnec M, Alvarez-Moya EM, Aguera Z, Aymami N, Gomez-Pena M, Del Pino-Gutierrez A, Moragas L, Menchon JM, Fagundo AB, Sauchelli S, La Verde M, Aguglia E, Signorelli MS, Formoso JAF, Fernandez-Aranda F. Pathological gambling and substance use disorders: effects of early incidence and personality. Drugs Health Society. 2015 Jan;14(1):78. doi: 10.7202/1035550ar